- Mesalamine 800-mg delayed-release tablets, referencing Asacol HD
- Lenalidomide capsules, referencing Revlimid
Amneal Pharmaceuticals Inc., a global biopharmaceutical company, today announced the launch of mesalamine 800-mg delayed-release tablets, an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults. The company also received approval from the FDA for its Abbreviated New Drug Application for lenalidomide capsules in 2.5-, 5-, 10-, 15-, 20- and 25-mg